Raludotatug Deruxtecan

6 trials 3 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

2 Sponsors

13 Countries

Phase II/III

Phase II

Phase I/II

Phase II/III: 2 Phase II: 3 Phase I/II: 1

Indications tested

Ovarian cancer 2 Cervix carcinoma 1 Non-small cell lung cancer stage IV 1 Fallopian tube cancer 1 Endometrial cancer 1 Small cell lung cancer extensive stage 1 Clear cell renal cell carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 4 Daiichi Sankyo Inc. 2

All trials

6 total

A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting

2024-518839-11-00 Phase II 6 countries Merck Sharp & Dohme LLC
A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting

2024-518761-10-00 Phase II 6 countries Merck Sharp & Dohme LLC
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Phase II/III 9 countries Daiichi Sankyo Inc.
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended

2024-513307-13-00 Phase II 5 countries Daiichi Sankyo Inc.
A clinical study of raludotatug deruxtecan in people with gastrointestinal cancers (MK-5909-005) Ended

2024-517416-30-00 Phase II/III 2 countries Merck Sharp & Dohme LLC
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC

Showing 1–6 of 6 trials

← All drugs A–Z